![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Karger
E-ISSN: 1421-9913|58|4|228-232
ISSN: 0014-3022
Source: European Neurology, Vol.58, Iss.4, 2007-09, pp. : 228-232
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?
Neuroepidemiology, Vol. 21, Iss. 6, 2002-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis
European Neurology, Vol. 59, Iss. 3-4, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
Medical Principles and Practice, Vol. 22, Iss. 5, 2013-06 ,pp. :